close

Agreements

Date: 2011-12-13

Type of information: Licensing agreement

Compound: PolyTherics’ TheraPEG™ conjugation technology

Company: Polytherics (UK) Nuron Biotech (USA)

Therapeutic area:

Type agreement:

licensing

Action mechanism:

Disease:

Details:

PolyTherics has announced that Nuron Biotech, Inc, a speciality biologics and vaccines company, has exercised its option to take a licence to PolyTherics’ TheraPEG™ conjugation technology to develop and commercialise a long-acting proprietary human interferon beta-1b (NU400). Nuron’s decision to take an exclusive worldwide licence for the application of TheraPEG™ follows its review of data generated by PolyTherics that demonstrates the efficiency of its conjugation chemistry for site-specific attachment of polyethylene glycol (PEG) to its proprietary human interferon beta-1b and the potency and extended half-life of the PEGylated interferon beta-1b.

Financial terms:

PolyTherics will receive an option fee from Nuron and is eligible for further milestone payments and royalties as Nuron progresses NU400 through development.

Latest news:

Is general: Yes